Literature DB >> 15694343

Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta.

Dennis H Dowhan1, Eugene P Hong, Didier Auboeuf, Andrew P Dennis, Michelle M Wilson, Susan M Berget, Bert W O'Malley.   

Abstract

Increasing evidence indicates that transcription and pre-mRNA processing are functionally coupled to modulate gene expression. Here, we report that two members of the U2AF65 family of proteins, hCC1.3, which we call CAPERalpha, and a related protein, CAPERbeta, regulate both steroid hormone receptor-mediated transcription and alternative splicing. The CAPER proteins coactivate the progesterone receptor in luciferase transcription reporter assays and alter alternative splicing of a calcitonin/calcitonin gene-related peptide minigene in a hormone-dependent manner. The importance of CAPER coactivators in the regulation of alternative RNA splicing of an endogenous cellular gene (VEGF) was substantiated by siRNA knockdown of CAPERalpha. Mutational analysis of CAPERbeta indicates that the transcriptional and splicing functions are located in distinct and separable domains of the protein. These results indicate that steroid hormone receptor-regulated transcription and pre-mRNA splicing can be directly linked through dual function coactivator molecules such as CAPERalpha and CAPERbeta.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694343     DOI: 10.1016/j.molcel.2004.12.025

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  90 in total

1.  The RNA polymerase C-terminal domain: a new role in spliceosome assembly.

Authors:  Charles J David; James L Manley
Journal:  Transcription       Date:  2011 Sep-Oct

Review 2.  Diverse regulation of 3' splice site usage.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2015-09-14       Impact factor: 9.261

3.  CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor₁₆₅ in Ewing sarcoma cells.

Authors:  Gangxiong Huang; Zhichao Zhou; Hua Wang; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

4.  A U1-U2 snRNP interaction network during intron definition.

Authors:  Wei Shao; Hyun-Soo Kim; Yang Cao; Yong-Zhen Xu; Charles C Query
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

Review 5.  A subset of nuclear receptor coregulators act as coupling proteins during synthesis and maturation of RNA transcripts.

Authors:  Didier Auboeuf; Dennis H Dowhan; Martin Dutertre; Natalia Martin; Susan M Berget; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

6.  Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription.

Authors:  Kyunghwan Kim; Jongkyu Choi; Kyu Heo; Hyunjung Kim; David Levens; Kimitoshi Kohno; Edward M Johnson; Hugh W Brock; Woojin An
Journal:  J Biol Chem       Date:  2008-02-07       Impact factor: 5.157

7.  Genomic functions of U2AF in constitutive and regulated splicing.

Authors:  Tongbin Wu; Xiang-Dong Fu
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 8.  Alternative splicing of G protein-coupled receptors: physiology and pathophysiology.

Authors:  Danijela Markovic; R A John Challiss
Journal:  Cell Mol Life Sci       Date:  2009-07-23       Impact factor: 9.261

9.  Bipartite functions of the CREB co-activators selectively direct alternative splicing or transcriptional activation.

Authors:  Antonio L Amelio; Massimo Caputi; Michael D Conkright
Journal:  EMBO J       Date:  2009-07-30       Impact factor: 11.598

10.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

Authors:  Taisuke Uehara; Yukinori Minoshima; Koji Sagane; Naoko Hata Sugi; Kaoru Ogawa Mitsuhashi; Noboru Yamamoto; Hiroshi Kamiyama; Kentaro Takahashi; Yoshihiko Kotake; Mai Uesugi; Akira Yokoi; Atsushi Inoue; Taku Yoshida; Miyuki Mabuchi; Akito Tanaka; Takashi Owa
Journal:  Nat Chem Biol       Date:  2017-04-24       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.